Cargando…

CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Epperly, Rebecca, Shulkin, Barry L., Bag, Asim K., Cheng, Cheng, Inaba, Hiroto, Lucas, John T., Naik, Swati, Triplett, Brandon M., Gottschalk, Stephen, Talleur, Aimee C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589782/ https://www.ncbi.nlm.nih.gov/pubmed/37595052 http://dx.doi.org/10.1182/bloodadvances.2023010461

Ejemplares similares

Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent and young adult patients with B-cell acute lymphoblastic leukemia
por: Petgrave, Yonique P, et al.
Publicado: (2023)

Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy
por: Maron, Gabriela M., et al.
Publicado: (2022)

A tour de force provides novel insights into CD19-CAR T cell resistance mechanisms
por: Talleur, Aimee C., et al.
Publicado: (2023)

Allogeneic CAR Cell Therapy—More Than a Pipe Dream
por: Caldwell, Kenneth J., et al.
Publicado: (2021)

Preferential expansion of CD8(+) CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL
por: Talleur, Aimee C., et al.
Publicado: (2022)

CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia
por: Zebley, Caitlin C., et al.
Publicado: (2021)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse
por: Wan, Xinyu, et al.
Publicado: (2022)

Selective depletion of naïve T cells by targeting CD45RA
por: Naik, Swati, et al.
Publicado: (2023)

Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
por: Epperly, Rebecca, et al.
Publicado: (2020)

A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
por: Epperly, Rebecca, et al.
Publicado: (2020)

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages
por: Wilson, Taylor L., et al.
Publicado: (2022)

PB2496: CAR-T CELLS THERAPY COMBINED WITH POMALIDOMIDE AGAINST RELAPSE AND REFRACTORY MM OR ALL WITH EXTRAMEDULLARY INVOLVEMENT
por: Zhao, Jie, et al.
Publicado: (2023)

Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution
por: Mamcarz, Ewelina, et al.
Publicado: (2019)

Efficacy and follow‐up of humanized anti‐BCMA CAR‐T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary‐extraosseous, extramedullary‐bone related, and without extramedullary disease
por: Li, Wei, et al.
Publicado: (2022)

Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia
por: Mo, George, et al.
Publicado: (2020)

Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
por: Diorio, Caroline, et al.
Publicado: (2022)

Multiple solitary extramedullary anaplastic plasmacytomas
por: Madi, Sandesh, et al.
Publicado: (2016)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Extramedullary leukemia in children presenting with proptosis
por: Murthy, Ramesh, et al.
Publicado: (2009)

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
por: Aparicio-Pérez, Clara, et al.
Publicado: (2023)

CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells
por: Hebbar, Nikhil, et al.
Publicado: (2022)

Bilateral orbital plasmacytomas as first sign of extramedullary progression post CAR-T therapy: case report and literature review
por: Nogués-Castell, Javier, et al.
Publicado: (2023)

Patrolling human SLE haematopoietic progenitors demonstrate enhanced extramedullary colonisation; implications for peripheral tissue injury
por: Kokkinopoulos, Ioannis, et al.
Publicado: (2021)

EXTRAMEDULLARY DISEASE
por: Beksac, Meral
Publicado: (2022)

Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma
por: Xia, Yuan, et al.
Publicado: (2022)

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
por: Weng, Jianyu, et al.
Publicado: (2018)

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
por: Deng, Haobin, et al.
Publicado: (2021)

Mechanism and effects of extramedullary hematopoiesis on anti-tumor immunity
por: Chen, Zefang, et al.
Publicado: (2023)

(11)C-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence
por: Bag, Asim K., et al.
Publicado: (2022)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

The potential for further exploration of extramedullary spinal tumors in Iranian patients
por: Patel, Anjali, et al.
Publicado: (2023)

Co-expressing LRP6 With Anti-CD19 CAR-T Cells for Improved Therapeutic Effect Against B-ALL
por: He, Ping, et al.
Publicado: (2020)

Correction to: A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
por: Weng, Jianyu, et al.
Publicado: (2019)

Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL
por: Zhang, Qiong, et al.
Publicado: (2019)

T-ALL Cells as Tool Cells for CAR T Therapy
por: Ren, Anqi, et al.
Publicado: (2023)

This CAR won’t start: predicting nonresponse in ALL
por: Webster, Jonathan A., et al.
Publicado: (2023)

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
por: Zurko, Joanna, et al.
Publicado: (2022)

Extramedullary gastric plasmacytoma.
por: Hamilton, J. W., et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_btb60lvlmb4prpeeimjse4futm